Recursion Pharmaceuticals, Inc. (RXRX) stock
RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/302% below fair value
$2.90−0.28 (-8.79%)
Close on Nov 16, 2026Market cap $1.56BP/E –Yield –
Recursion Pharmaceuticals total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Recursion Pharmaceuticals's total debt was $14.20M at Jun 30, 2026. For fiscal 2025 it was $18.66M, down 32.0% from the year before. The highest annual figure on record is $27.45M in fiscal 2024.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.66M | -32.0% |
| FY2024 | Dec 31, 2024 | $27.45M | +2303.4% |
| FY2023 | Dec 31, 2023 | $1.14M | +113.1% |
| FY2022 | Dec 31, 2022 | $536.00K | -15.3% |
| FY2021 | Dec 31, 2021 | $633.00K | -94.5% |
| FY2020 | Dec 31, 2020 | $11.41M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $14.20M | -38.1% |
| Q1 FY2026 | Mar 31, 2026 | $16.45M | -34.3% |
| Q4 FY2025 | Dec 31, 2025 | $18.66M | -32.0% |
| Q3 FY2025 | Sep 30, 2025 | $20.82M | -27.5% |
| Q2 FY2025 | Jun 30, 2025 | $22.95M | -26.0% |
| Q1 FY2025 | Mar 31, 2025 | $25.03M | +2237.3% |
| Q4 FY2024 | Dec 31, 2024 | $27.45M | +2303.4% |
| Q3 FY2024 | Sep 30, 2024 | $28.73M | +2451.4% |
| Q2 FY2024 | Jun 30, 2024 | $31.03M | +2586.6% |
| Q1 FY2024 | Mar 31, 2024 | $1.07M | -9.2% |
| Q4 FY2023 | Dec 31, 2023 | $1.14M | +113.1% |
| Q3 FY2023 | Sep 30, 2023 | $1.13M | +100.7% |
| Q2 FY2023 | Jun 30, 2023 | $1.16M | +97.1% |
| Q1 FY2023 | Mar 31, 2023 | $1.18M | +93.3% |
| Q4 FY2022 | Dec 31, 2022 | $536.00K | -15.3% |
| Q3 FY2022 | Sep 30, 2022 | $561.00K | -14.5% |
| Q2 FY2022 | Jun 30, 2022 | $586.00K | -93.8% |
| Q1 FY2022 | Mar 31, 2022 | $610.00K | -94.1% |
| Q4 FY2021 | Dec 31, 2021 | $633.00K | -94.5% |
| Q3 FY2021 | Sep 30, 2021 | $656.00K | – |
| Q2 FY2021 | Jun 30, 2021 | $9.42M | – |
| Q1 FY2021 | Mar 31, 2021 | $10.34M | – |
| Q4 FY2020 | Dec 31, 2020 | $11.41M | – |
See a number that looks wrong?